This SHP2 Target Evaluation Report is generated from PatSnap MCP data. PTPN11 / SHP2 is a central RAS/MAPK signaling node in NSCLC, with clinical development focused on KRAS G12C combinations, EGFR-mutant resistance, and pathway-feedback suppression.

This SOS1 Target Evaluation Report is generated from PatSnap MCP data. SOS1 is a RAS pathway target with active early clinical competition in KRAS-mutant tumors, but Clinical Trials MCP did not return released result records for the selected SOS1 solid-tumor query, making this a high-interest but still readout-light target.

This ROR1 Target Evaluation Report is generated from PatSnap Target & Disease MCP and Clinical Trials MCP data. ROR1 is an oncology target with compelling tumor-associated expression and active clinical exploration in CLL, but the evidence base is still earlier and more selective than mature hematology targets.

This PSMA Target Evaluation Report is generated from PatSnap MCP data. FOLH1 / PSMA is one of the most clinically validated prostate cancer targets, with a dense radioligand, imaging, and targeted-therapy ecosystem reflected by 577 Clinical Trials MCP trial records and 405 result records.

MDM2 is niche but compelling in liposarcoma, where focused evidence matters more than raw trial volume.

FGFR3 is a focused urothelial carcinoma target with biomarker-driven opportunity.

FLT3 is a highly validated AML target with active opportunity in combinations, maintenance, and resistance-focused development.

IDH1 is a focused, clinically validated AML target with remaining opportunity in combination and sequencing strategy.

PARP1 is a validated ovarian cancer target, with new opportunity concentrated in biomarker precision and combination strategy.

AR is one of oncology’s most validated targets, but new value requires resistance-focused or modality-differentiated strategy.

BRAF is a highly validated melanoma target, but competition is mature and strategy must focus on resistance, CNS, or combination innovation.

RET is a validated precision-oncology target with meaningful remaining development space, especially in resistance and earlier lines.